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ABSTRACT
Objectives: To explore (1) the national trend in
population-adjusted prescription rates for glaucoma
and ocular hypertension (OHT) in England and (2) any
geographical variation in glaucoma/OHT prescribing
trends and its association with established risk factors
for primary open-angle glaucoma (POAG) at the
population level.
Design: Observational ecological study.
Setting: Primary care in England 2008–2012.
Participants: All patients who received 1 or more of
the 37 778 660 glaucoma/OHT prescription items
between 2008 and 2012.
Primary and secondary outcome measure
methods: Glaucoma/OHT prescription statistics for
England and its constituent primary care trusts (PCTs)
between 2008 and 2012 were divided by annual
population estimates to give prescription rates per
100 000 population aged ≥40 years. To examine
regional differences, prescription rates and the change
in prescription rates between 2008 and 2012 for PCTs
were separately entered into multivariable linear
regression models with the population proportion aged
≥60 years; the proportion of males; the proportion of
West African Diaspora (WAD) ethnicity; PCT funding
per capita; Index of Multiple Deprivation 2010 score
and its domains.
Results: Between 2008 and 2012, glaucoma/OHT
prescriptions increased from 28 029 to 31 309 items
per 100 000 population aged ≥40 years. Between
PCTs, nearly a quarter of the variation in prescription
rates in 2008 and 2012 could be attributed to age,
WAD ethnicity and male gender. The change in
prescription rates between 2008 and 2012 was only
modestly correlated with age (p=0.003, β=0.234), and
income deprivation (p=0.035, β=−0.168).
Conclusions: Increased population-adjusted
glaucoma/OHT prescription rates in the study period
were likely due to increased detection of POAG and
OHT cases at risk of POAG. Between PCTs, regional
variation in overall prescription rates was partly
attributable to demographic risk factors for POAG,
although the change in prescription rates was only
modestly correlated with the same risk factors,
suggesting potential variation in practice.
INTRODUCTION
Glaucoma, a group of eye conditions with a
characteristic type of optic nerve damage
(cupping) and visual ﬁeld defects, accounted
for around 8% of registered blindness in
England and Wales in 2008, making it the
second leading cause of certiﬁed visual loss
after age-related macular degeneration in
these countries.1 Primary open-angle glau-
coma (POAG), characterised by normal
appearance of the iridocorneal angle, is the
predominant form of glaucoma and
accounts for around 74% of all glaucoma
cases worldwide.2 POAG as the proportion of
all glaucoma cases is likely to be higher in
England, where widespread cataract surgery
has been associated with a dramatic decline
in primary angle closure glaucoma (PACG),3
the second major form of glaucoma.2
Cataract surgery is thought to reduce the
Strengths and limitations of this study
▪ Population-based data for the whole of England
over a period of 4 years.
▪ Geographically linked prescription data covered
almost 99% of all community glaucoma/ocular
hypertension (OHT) prescriptions in public
healthcare, allowing analysis of prescription data
with relevant demographic and socioeconomic
data on a population level.
▪ Prescription data were not linked to individual
patient records, which precluded calculation of
actual patient numbers and the distinction of
prescriptions dispensed for glaucoma from those
dispensed for OHT.
▪ Lack of data on glaucoma/OHT prescriptions in
private medical care.
▪ Data only allowed comparison of regional differ-
ences in prescription rates between primary care
trusts but not variation with each trust, with each
trust covering a wide geographical area and a
large population.
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incidence of PACG by removing the lens in older indivi-
duals and thus preventing ‘angle closure’ due to pro-
gressive age-related lens thickening causing occlusion of
the iridocorneal angle.3 In absolute terms, POAG is esti-
mated to affect at least 500 000 individuals in the UK.4
Two developments in England in the past decade
might have led to an increase in the number of people
who receive treatment for POAG. First, an ageing popu-
lation proﬁle due to rising life expectancy in the UK
would result in a proportion of the population at risk of
POAG.5 Denmark, a similarly developed country with an
ageing population proﬁle, was indeed found to have a
rising prevalence of glaucoma in a recent study.6
Second, the National Institute of Health and Care
Excellence (NICE) published a set of clinical guidelines
in April 2009 concerning the diagnosis and manage-
ment of POAG and ocular hypertension (OHT) to
address uncertainty and variation in clinical practice.4
‘OHT’ is a term commonly used to describe a condition
in which the intraocular pressure (IOP) is elevated
above 21 mm Hg without clinical evidence of glaucomat-
ous optic nerve damage or visual ﬁeld deﬁcits,4 although
a signiﬁcant proportion of patients with OHT progress
to develop POAG.7 The NICE guidelines4 recommended
treatment of OHT in patients deemed at high risk of
progression to POAG with IOP-lowering medications
that are also used to treat POAG, as this approach has
been shown to be cost-effective in reducing progression
to POAG.7 8 Since the introduction of the NICE guide-
lines, local increases in glaucoma referrals9–11 and in
glaucoma case detection have been reported.10 11 It has
also been observed that the annual total number of
glaucoma/OHT prescriptions in England had increased
by 67% between 2000 and 2012.12 However, the changes
in prescription rates relative to the underlying popula-
tion, which would indicate any change in the population
prevalence of treated glaucoma and OHT, have not
been examined.
Any increase in rates of glaucoma/OHT prescriptions,
however, might not be equally shared between the differ-
ent regions in England. Malik et al13 has shown a nearly
ﬁvefold variation in outpatient ophthalmology expend-
iture in the ﬁscal year 2009/2010 between different
regions in England, even after adjusting for age, sex and
socioeconomic deprivation. The rates of trabeculectomy,
the mainstay of surgical treatment for POAG, were also
shown to have widespread geographical variation.14 It is
not known whether any geographical variation in glau-
coma/OHT treatment was associated with differences in
populations at risk between these regions.
A few risk factors have been well established for
POAG. There are likely genetic inﬂuences in the devel-
opment of POAG, although twin studies show only a
modest, albeit signiﬁcant, inheritability index.15 16
Family history is important as having an affected ﬁrst-
degree relative increases the risk of developing POAG by
10 times.15 POAG is more common in people of the
West African Diaspora (WAD) including African
Caribbean or British West Indian people and African–
Americans, compared with Europeans or Asians.17 18
The association of gender with the risk of POAG has
been controversial,19 with conﬂicting results from differ-
ent studies. Variation in study methods, small sample
sizes and differences in the populations studied are
likely to account for the inconsistent results seen. An
extensive meta-analysis performed by Rudnicka et al19
included 61 267 POAG cases and reported POAG to be
around 1.4 times more common in men than that in
women, which is consistent with previous prescribing
data from the UK.20 Most importantly, the incidence of
POAG is known to rise with age. POAG is rare before
the age of 4019 21 22 (but more common in people of
the WAD) and has an OR of around 2 for every increase
of a decade in age from the age of 40,19 with a mean
age of onset of around 60 years of age.21 22 The popula-
tion aged 40 years and over can therefore be considered
the primary population at risk.
The objectives of this study were to explore (1) the
national trend in population-adjusted prescription rates
for glaucoma and OHT in England and (2) any geo-
graphical variation in glaucoma/OHT prescribing
trends and its association with established risk factors for
POAG at the population level.
METHODS
Data collection
The National Health Service (NHS) in England, the
largest single-payer publicly funded healthcare system in
the world, was administered through 10 regional bodies
called strategic health authorities (SHAs). SHAs were
further subdivided into 151 local bodies called primary
care trusts (PCTs) from October 2006 to March 2013.
Each PCT responsible for a geographical area commis-
sioned primary, community and secondary health ser-
vices from providers, including hospitals. PCTs were
collectively responsible for spending around 80% of the
total NHS budget, accounting for a total expenditure of
£164 billion in the ﬁnancial years 2009/2010 and 2010/
2011.23
General population data in England were derived
from population census data. In England, the popula-
tion census is conducted every 10 years, with the most
recent census being conducted in 2011. Data from the
2011 census for the English population aged ≥40,
≥60 years, the number of males and the number of
people of WAD ethnicity were tabulated for England
overall and for each PCT. Mid-year population estimates
from the Ofﬁce of National Statistics were obtained for
England and for each PCT to account for the variation
in population each year. The number of people of WAD
ethnicity was tabulated by the summation of the popula-
tion counts under the categories ‘African’, ‘Caribbean’,
‘other black’, ‘mixed: white and black African’ and
‘mixed: white and black Caribbean’ in the 2011 census.
The measure of each demographic group per 100 000
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population was obtained by dividing the total number in
the group by the total population and multiplying by
100 000.
The total number of annual prescriptions for glau-
coma or OHT dispensed in the community, including
those prescribed in hospital and dispensed in the com-
munity, was obtained for the whole of England for each
of the ﬁnancial years between 2008/2009 and 2012/
2013 from the Health and Social Care Information
Centre website.24 Separate annual data on prescriptions
for the treatment of glaucoma or OHT, based on the
reimbursement to dispensers for supplying products on
prescription, were obtained for each PCT for the same
period.24 The PCT data covered prescriptions dispensed
in the community in the UK that were prescribed by
general practitioners, nurses, pharmacists and other pre-
scribers in the community in England. Prescriptions
written in hospitals/clinics that were dispensed in the
community as well as prescriptions dispensed in hospi-
tals and private prescriptions were not included in the
PCT data.
To explore whether the change in glaucoma/OHT
prescription rates was associated with socioeconomic
factors, the 2010 Index of Multiple Deprivation (IMD)
score25 was collected for each PCT. The IMD is a stan-
dardised index used in England as a measure of socio-
economic deprivation, and is constructed from seven
different domains with the following weightage: (1)
income—22.5%; (2) employment—22.5%; (3) health
and disability—13.5%; (4) education, skills and training
—13.5%; (5) barriers to housing and services—9.3%;
(6) crime—9.3%; (7) living environment—9.3%. In
general, the higher the IMD or domain score, the more
deprived an area is.25 In particular, we investigated spe-
ciﬁc domain scores of interest including income,
employment, health and disability, education, skills and
training, as well as barriers to housing and services.
To investigate if overall healthcare funding could
account for differences in glaucoma/OHT prescribing
rates, total funding allocation and funding allocation
per capita for each PCT were obtained for the ﬁnancial
year 2011/2012 from the Department of Health.
Calculation of prescription rates
The prescription rate was adjusted for the underlying
population by dividing the number of prescriptions by
the corresponding population estimate in the same year,
and multiplying by 100 000 to give a prescription rate
per 100 000 population. For the purposes of analysis in
this study, the prescription rate per 100 000 of popula-
tion aged ≥40 years was used, as this age group is consid-
ered the primary population at risk. The change in
number of PCT prescriptions was calculated by subtract-
ing the prescription rate in 2008/2009 from that in
2012/2013. The annual increment in prescription rate,
which would indicate the number of new cases treated
for glaucoma or OHT each year adjusted for the
underlying population at risk, was calculated by subtract-
ing the prescription rate in 1 year from the preceding
year.
Statistical analysis
PCTs were anonymised by converting PCT names into
serial numbers before data analysis. Glaucoma/OHT
prescription rates and the change in glaucoma/OHT
prescription rates of PCTs were separated into quintiles
and plotted on choropleth maps of England PCT
boundaries using the Quantum Geographical
Information System (QGIS) V.2.4 for Macintosh OS.
Statistical analyses were conducted using SPSS Statistics
software V.21.0 for Macintosh OS. Any missing data were
excluded from analysis by pairwise deletion. Pairwise
correlations of continuous variables were carried out
using Spearman’s rank correlation. Correlation between
multiple continuous variables and prescription rates
were examined using multivariable linear regression.
Multivariable linear regression was conducted in a
forward conditional fashion, and variables ﬁtted in the
ﬁnal model were examined for collinearity using their
tolerance and variance inﬂation factor (VIF) values.
Tolerance values of >0.1 and VIF values of <10 were
taken to indicate the non-redundancy of variables and
the consequent stability of the model(s). p Values of
<0.05 were considered statistically signiﬁcant.
RESULTS
There were no missing data. The total population in
England increased from 49.1 million in the 2001 census
to 53.0 million in the 2011 census (table 1). In the same
period, the population aged ≥40 years rose from 22.9 to
26.0 million (an increase from 46.6% to 49.1% of total
population), while the population aged ≥60 years rose
10.2–11.8 million (an increase from 20.1% to 22.3% of
the total population). The population of WAD ethnicity
rose from 1.4 to 2.4 million (an increase from 2.9% to
4.5% of total population).
The total number of prescription items for glaucoma/
OHT in England increased from 7.03 million items at a
net cost of £97.6 million in 2008/2009 to 8.23 million
items at a net cost of £105.2 million in 2012/2013. PCT
prescriptions for glaucoma/OHT medications
accounted for 98.7% of all community glaucoma/OHT





Age ≥40 years 22 940 410 (46.7) 25 995 642 (49.0)
Age ≥60 years 10 199 830 (20.8) 11 832 806 (22.3)
WAD ethnicity 1 440 430 (2.93) 2 423 780 (4.57)
Males 23 922 144 (49.0) 26 069 148 (49.2)
Total population 49 138 831 (100) 53 012 456 (100)
WAD, West African Diaspora.
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prescriptions in 2008/2009 and for 99.0% in 2012/2013.
When adjusted for population using mid-year estimates
for the corresponding ﬁnancial year, the number of pre-
scription items increased from 28 029 to 31 309 items
per 100 000 of the population aged ≥40 years during
this period (ﬁgure 1). There was a year-on-year increase
in the annual increment in prescription rates from
2009/2010 to 2011/2012 but the annual increment
tailed off in 2012/2013 (ﬁgure 1). Between 2009/2010
and 2011/2012, the annual increment increased from
597 to 1100 per 100 000 of population aged ≥40 years,
suggesting an increase in the annual incidence of new
patients being treated for glaucoma or OHT in these
years.
In the 2011 census, the median population in each
PCT was 288 283, and the median population aged
≥40 years in each PCT was 129 634. Across PCTs, the
median prescription rates per 100 000 population aged
≥40 years were 26 792 (IQR=7222) and 30 006
(IQR=8827) in 2008/2009 and 2012/2013, respectively.
Between 2008/2009 and 2012/2013, there was an
increase in the absolute number of prescription items
for glaucoma/OHT for every PCT, with a median
increase of 5900 items per PCT. When adjusted for
population aged ≥40 years, there was an increase in the
number of prescription items in all but six PCTs. The
median increase per PCT was 2875 items per 100 000
population aged ≥40 years (IQR=2849).
Regional differences in prescriptions per 100 000
population aged ≥40 years were apparent between PCTs
in 2008/2009 (ﬁgure 2) and 2012/2013 (ﬁgure 3) with
a nearly 3fold variation between the top and bottom
quintiles. The change in prescription items per 100 000
of population aged ≥40 years showed even more pro-
nounced regional differences with a nearly tenfold vari-
ation between the top and bottom quintiles (ﬁgure 4).
The prescription rate per 100 000 population aged
≥40 years in 2008/2009 and 2012/2013 as well as the
change in prescription rates between these 2 years for
each PCT were separately correlated to the population
aged ≥60 years per 100 000 aged ≥40 years, the number
of males per 100 000 population, the number people of
WAD ethnicity per 100 000 population, IMD 2010 score
and its domains of interest and the total PCT fund allo-
cation per capita using forward multivariable linear
regression models. Prescriptions per 100 000 population
aged ≥40 years in 2008/2009 (table 2) were positively
correlated with the population aged ≥60 years per
100 000 aged ≥40 years (p<0.001, β=0.776), IMD 2010
income deprivation score (p=0.013, β=0.186), WAD eth-
nicity per 100 000 population (p=0.006, β=0.349) and
males per 100 000 population (p=0.023, β=0.197).
Prescriptions per 100 000 population aged ≥40 years in
2012/2013 (table 3) were positively correlated with the
population aged ≥60 years per 100 000 aged ≥40 years
(p<0.001, β=0.842), WAD ethnicity per 100 000 popula-
tion (p=0.003, β=0.403) and males per 10 000 popula-
tion (p=0.010, β=0.184). The change in prescriptions
per 100 000 population aged ≥40 years between 2008/
2009 and 2012/2013 (table 4) was positively correlated
with the population aged ≥60 years per 100 000 aged
≥40 years (p=0.003, β=0.234), and negatively correlated
with the IMD 2010 income deprivation score (p=0.035,
β=−0.168). All tolerance values were above 0.1 and VIF
values were <10, indicating that the models were stable.
Univariable linear regression plots of the change in pre-
scriptions per 100 000 population aged ≥40 years
between 2008/2009 and 2012/2013 against the popula-
tion aged ≥60 years per 100 000 aged ≥40 years
(ﬁgure 5A) and the IMD 2010 income deprivation score
(ﬁgure 5B) are shown. There was no correlation
between the change in prescription items per 100 000 of
Figure 1 Glaucoma/OHT
prescriptions in England 2008–
2012. Glaucoma/OHT
prescriptions per 100 000
population aged 40 years and
over are plotted as bar graphs
and annual increment in
glaucoma/OHT prescription rate
is plotted as a line graph. OHT,
ocular hypertension.
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population aged ≥40 years and prescriptions per
100 000 of population aged ≥40 years in 2008/2009
(Spearman r=0.073, p=0.373).
DISCUSSION
In this study, we showed that the number of prescrip-
tions for glaucoma/OHT medications had increased
almost universally in England between 2008 and 2012
even after accounting for the increase in the primary
population at risk of POAG (age ≥40 years). Moreover,
the year-on-year increase in annual increment of pre-
scription rates adjusted for the population at risk
between 2008 and 2012 suggests an increase in the
annual incidence of new patients being treated for glau-
coma or OHT in these years. Assuming a constant popu-
lation risk, this increase would suggest an increase in
detection, rather than the true incidence, of predomin-
antly POAG and OHT cases at risk of POAG. We also
showed widespread geographical variation in
population-adjusted glaucoma/OHT prescription rates
which could be partially accounted for by risk factors for
POAG, although the change in population-adjusted
glaucoma/OHT prescription rates between 2008 and
2012 was only modestly correlated with the same risk
factors.
The rise in the total number of glaucoma/OHT pre-
scriptions in England over the past decade has been well
documented.12 There were likely multiple factors under-
lying the change in glaucoma/OHT prescribing in such
a large population, such as an ageing population, lower
IOP targets and polypharmacy. An ageing population
due to rising life expectancy, as evidenced by an increase
in the population aged ≥40 years, was likely to drive a
long-term increase in the prevalence of glaucoma and
OHT. However, assuming a constant population at risk
would mean that the population-adjusted incidence of
new glaucoma/OHT cases should stay roughly constant
over the span of a few years, unless there was a signiﬁ-
cant change in practice. Owing to our study period and
the temporal trends in annual population-adjusted pre-
scription rates as discussed above, we could not exclude
the possible impact of the NICE 2009 guidelines on
glaucoma/OHT treatment. The NICE guidelines were
Figure 2 Choropleth map of England PCTs showing glaucoma/OHT prescriptions per 100 000 population aged ≥40 years in
2008/2009, divided into quintiles. OHT, ocular hypertension; PCT, primary care trust.
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the ﬁrst national guidelines in England on specifying
the threshold, timing and mode of treatment in glau-
coma and OHT. Following the publication of the NICE
guidelines, previous studies have demonstrated an
increase in the number of local glaucoma referrals.9–11
Rather than purely due to a direct impact of the NICE
guidelines themselves, this increase might be partly due
to the recommendation by the Association of
Optometrists (AOP) in response to the NICE guidelines
that all patients with a single measurement of IOP over
21 mm Hg should be referred to an ophthalmologist
regardless of the type of tonometer used for measure-
ment.26 The usefulness of this recommendation has
been questioned,9 as it has led to an increased number
of referrals for an isolated ﬁnding of an IOP >21 mm Hg
since 2009 associated with a higher number of false posi-
tives.9 10 Subsequent studies have found a small increase
in the absolute number of detected glaucoma cases at
the expense of a fall in case detection rate.10 11 Our
ﬁnding of an increase in the annual increment of pre-
scription rates would suggest that there was a rise in the
annual number of detected glaucoma and OHT cases
across England in the study period, although our data
could not examine the false-positive rate.
Overall, there was a threefold variation in
population-adjusted glaucoma/OHT prescription rates
across different PCTs. In multivariable linear regression
models, up to a quarter of this variation could be
accounted for by known risk factors for POAG in 2008/
2009 and 2012/2013. These factors were namely age,
WAD ethnicity and male gender. Unsurprisingly, age, as
measured by proportion aged ≥60 years per 100 000
population aged ≥40 years, accounted for the most vari-
ation in these models—14.3% and 19.0% of the vari-
ation between PCTs in 2008/2009 and 2012/2013,
respectively. The rise in contribution of age to the vari-
ation between PCTs during the study period was also
reﬂected in the positive correlation of age with the
change in prescription rates between 2008/2009 and
2012/2013. The positive correlation of male gender with
glaucoma/OHT prescription rates is consistent with a
previous extensive study on glaucoma prescribing in
England20 but is contrary to the ﬁndings in a recent
nationwide study of glaucoma prevalence and treatment
Figure 3 Choropleth map of England PCTs showing glaucoma/OHT prescriptions per 100 000 population aged ≥40 years in
2012/2013, divided into quintiles. OHT, ocular hypertension; PCT, primary care trust.
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in Denmark.6 The discrepancy in the association of
gender in this instance is likely to be due to differences
in the underlying population.
The possible reasons for the small positive correlation
between income deprivation and population-adjusted
glaucoma/OHT prescription rates between PCTs in
2008/2009 as well as the subsequent small negative cor-
relation between income deprivation and the change in
prescription rates between 2008/2009 and 2012/2013
remain unclear. Socioeconomic deprivation has been
associated with late presentation to clinical services and
visual loss in patients with glaucoma,27–30 but the impact
of these ﬁndings on overall prescription rates is
unknown.
Across England, there was a nearly 10-fold variation in
the change in glaucoma/OHT prescriptions between
Figure 4 Choropleth map of England PCTs showing change in glaucoma/OHT prescriptions per 100 000 population aged
≥40 years between 2008/2009 and 2012/2013, divided into quintiles. OHT, ocular hypertension; PCT, primary care trust.
Table 2 Multivariable linear regression model for glaucoma/OHT prescription rate per 100 000 population aged ≥40 years in
2008/2009





Proportion of population aged ≥60 years per
100 000 aged ≥40 years
0.931 (0.609 to 1.254) 0.776 <0.001 0.143 0.275 3.639
Income deprivation 0.047 (0.010 to 0.084) 0.186 0.013 0.059 0.929 1.076
WAD ethnicity per 100 000 0.297 (0.088 to 0.507) 0.349 0.006 0.028 0.329 3.037
Males per 100 000 1.691 (0.233 to 3.148) 0.197 0.023 0.027 0.690 1.449
R2=0.257, adjusted R2=0.236.
OHT, ocular hypertension; VIF, variance inflation factor; WAD, West African Diaspora.
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PCTs in the top and bottom quintiles between 2008/
2009 and 2012/2013. Compared with the variation in
overall population-adjusted prescription rates, only a
small fraction (around 8%) of the variation in this
change in prescription rates could be explained by the
variables examined in this study, indicating that demo-
graphic factors were not the predominant drivers
behind the change in prescription rates across PCTs in
our study period. This supports the notion that changes
in practice were more likely responsible for the change
in prescription rates.
Other factors which might have contributed further to
variation in prescription rates as well as the change in pre-
scription rates are more likely to relate to actual individual
risk, such as family history and genetics, which are difﬁcult
to assess at a population level. Variation in practices of
eye-care professionals between regions were also likely to
have contributed to regional variations in prescriptions.
A major limitation of this study was that data on pre-
scription items were not linked to individual patient
records, which precluded the possibility of calculating
the actual number of treated patients with glaucoma/
OHT. As such, we were unable to exclude one-time pre-
scriptions of IOP-lowering medications that could follow
certain ocular surgeries (eg, cataract surgery, retina
detachment surgery), although the contribution of such
prescriptions to the total number of prescriptions was
likely to be small. We also could not distinguish prescrip-
tion items dispensed for glaucoma from those dispensed
for OHT since the same medications are prescribed for
both conditions. Another limitation was the lack of data
on glaucoma/OHT prescriptions in private medical
care. Having private prescription data would allow the
elucidation of the actual burden of medical treatment
for glaucoma/OHT in England. Finally, our study
method was designed to examine regional differences in
prescription rates between PCTs, but not variation
within each PCT, which had a median population of
over 200 000 in the 2011 census.
In conclusion, our study showed that
population-adjusted glaucoma/OHT prescription rates
in England were increasing. We also showed that
although geographical variation in overall prescription
rates was partially correlated with known demographic
risk factors for POAG, the change in prescription rates
in the study period was only modestly correlated with
the same demographic risk factors. With an ageing
population proﬁle, the increasing healthcare burden of
glaucoma is a formidable one. The total cost of medical
treatment currently stands at £105.2 million in the ﬁnan-
cial year 2012/2013—an increase of £7.6 million since
2008/2009. The total cost of medical treatment would
have been higher except for a decrease in the unit cost
of the most commonly prescribed glaucoma medication,
latanoprost, due to the expiry of its patent in January
2012.12 The actual costs of managing glaucoma in the
National Health System, however, are likely to be much
higher with the increased number of referrals, monitor-
ing for an increased number of patients, and surgery for
selected patients,31 32 which have not been calculated in
this study. It is likely that variations in practice exist,
which may impede the efﬁcient allocation of resources
for glaucoma treatment. Further investigation into such
variation in practice is warranted, such that practice can
be standardised to deliver uniform and equitable health-
care for all patients with glaucoma.
Table 3 Multivariable linear regression model for glaucoma/OHT prescription rate per 100 000 population aged ≥40 years in
2012/2013





Proportion of population aged ≥60 years per
100 000 aged ≥40 years
1.110 (0.760 to 1.459) 0.842 <0.001 0.190 0.281 3.557
WAD ethnicity per 100 000 0.345 (0.120 to 0.569) 0.403 0.003 0.033 0.344 2.905
Males per 100 000 2.076 (0.505 to 3.648) 0.184 0.010 0.034 0.712 1.405
R2=0.257, adjusted R2=0.242.
OHT, ocular hypertension; VIF, variance inflation factor; WAD, West African Diaspora.
Table 4 Multivariable linear regression model for change in glaucoma/OHT prescription rate per 100 000 population aged
≥40 years from 2008/2009 to 2012/2013





Proportion of population aged ≥60 years per
100 000 aged ≥40 years
0.112 (0.038 to 0.187) 0.234 0.003 0.064 0.989 1.012
Income deprivation − 0.017 (−0.033 to −0.001) −0.168 0.035 0.028 0.989 1.012
R2=0.092, adjusted R2=0.079.
OHT, ocular hypertension; VIF, variance inflation factor.
8 Heng JS, et al. BMJ Open 2016;6:e010429. doi:10.1136/bmjopen-2015-010429
Open Access
Acknowledgements The authors would like to thank the Office of National
Statistics (ONS) for providing population data, the Health and Social Care
Information Centre (HSCIC) for providing NHS administrative data and the
Department of Health (DH) for providing statistics on funding and workforce.
Contributors JSH performed data collection and statistical analysis. JSH, RW
and PTK contributed to the drafting, editing and proof-reading of the
manuscript.
Funding This research received no specific grant from any funding agency in
the public, commercial or not-for-profit sectors. RW and PTK were supported
in part by the National Institute for Health Research (NIHR) Biomedical
Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL
Institute of Ophthalmology.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement Original prescription data available from http://www.
hscic.gov.uk/prescribing.
Open Access This is an Open Access article distributed in accordance with
the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license,
which permits others to distribute, remix, adapt, build upon this work non-
commercially, and license their derivative works on different terms, provided
the original work is properly cited and the use is non-commercial. See: http://
creativecommons.org/licenses/by-nc/4.0/
REFERENCES
1. Bunce C, Xing W, Wormald R. Causes of blind and partial sight
certifications in England and Wales: April 2007–March 2008.
Eye (Lond) 2010;24:1692–9.
2. Quigley HA, Broman AT. The number of people with glaucoma
worldwide in 2010 and 2020. Br J Ophthalmol 2006;90:262–7.
3. Keenan TDL, Salmon JF, Yeates D, et al. Trends in rates of primary
angle closure glaucoma and cataract surgery in England from 1968
to 2004. J Glaucoma 2009;18:201–5.
4. National Institute of Clinical Excellence. Glaucoma—diagnosis and
management of chronic open angle glaucoma and ocular
hypertension. NICE Clinical Guideline 85, 2009.
5. Tuck MW, Crick RP. The projected increase in glaucoma due to an
ageing population. Ophthalmic Physiol Opt 2003;23:175–9.
6. Kolko M, Horwitz A, Thygesen J, et al. The prevalence and
incidence of glaucoma in Denmark in a fifteen year period:
a nationwide study. PLoS ONE 2015;10:e0132048.
7. Kass MA, Heuer DK, Higginbotham EJ, et al. The ocular
hypertension treatment study: a randomized trial determines that
topical ocular hypotensive medication delays or prevents the onset
of primary open-angle glaucoma. Arch Ophthalmol
2002;120:701–13; discussion 829–30.
8. Kymes SM, Kass MA, Anderson DR, et al. Management of ocular
hypertension: a cost-effectiveness approach from the Ocular
Hypertension Treatment Study. Am J Ophthalmol
2006;141:997–1008.
9. Shah S, Murdoch IE. NICE—impact on glaucoma case detection.
Ophthalmic Physiol Opt 2011;31:339–42.
10. Ratnarajan G, Newsom W, French K, et al. The effect of changes in
referral behaviour following NICE guideline publication on agreement
of examination findings between professionals in an established
glaucoma referral refinement pathway: the Health Innovation &
Education Cluster (HIEC) Glaucoma Pathways project.
Br J Ophthalmol 2013;97:210–14.
11. de Silva SR, Riaz Y, Purbrick RMJ, et al. There is a trend for the
diagnosis of glaucoma to be made at an earlier stage in 2010
compared to 2008 in Oxford, United Kingdom. Ophthalmic Physiol
Opt 2013;33:179–82.
12. Connor AJ, Fraser SG. Glaucoma prescribing trends in England
2000 to 2012. Eye (Lond) 2014;28:863–9. .
13. Malik ANJ, Cassels-Brown A, Wormald R, et al. Better value eye
care for the 21st century: the population approach. Br J Ophthalmol
2013;97:553–7.
14. Keenan TDL, Salmon JF, Yeates D, et al. Trends in
rates of trabeculectomy in England. Eye (Lond) 2009;
23:1141–9.
15. Wolfs RC, Klaver CC, Ramrattan RS, et al. Genetic risk of primary
open-angle glaucoma. Population-based familial aggregation study.
Arch Ophthalmol 1998;116:1640–5.
16. Teikari JM. Genetic factors in open-angle (simple and capsular)
glaucoma. A population-based twin study. Acta Ophthalmol
1987;65:715–20.
17. Tielsch JM, Sommer A, Katz J, et al. Racial variations in the
prevalence of primary open-angle glaucoma. The Baltimore Eye
Survey. JAMA 1991;266:369–74.
18. Racette L, Wilson MR, Zangwill LM, et al. Primary
open-angle glaucoma in blacks: a review. Surv Ophthalmol
2003;48:295–313.
19. Rudnicka AR, Mt-Isa S, Owen CG, et al. Variations in primary
open-angle glaucoma prevalence by age, gender, and race:
a Bayesian meta-analysis. Invest Ophthalmol Vis Sci
2006;47:4254–61.
20. Owen CG, Carey IM, De Wilde S, et al. The epidemiology of medical
treatment for glaucoma and ocular hypertension in the
United Kingdom: 1994 to 2003. Br J Ophthalmol
2006;90:861–8.
21. Leske MC, Connell AM, Wu SY, et al. Incidence of open-angle
glaucoma: the Barbados Eye Studies. The Barbados Eye Studies
Group. Arch Ophthalmol 2001;119:89–95.
22. Mukesh BN, McCarty CA, Rait JL, et al. Five-year incidence of
open-angle glaucoma: the visual impairment project. Ophthalmology
2002;109:1047–51.
23. Thompson G. Primary care trusts: Funding and expenditure.
Standard Note: SN/SG/5719, House of Commons Library. 2010;
http://researchbriefings.files.parliament.uk/documents/SN05719/
SN05719.pdf (accessed 1 July 2015).
Figure 5 Univariable linear regression plots showing correlation between (A) change in glaucoma/OHT prescriptions per
100 000 aged ≥40 years with population aged ≥60 years per 100 000 aged ≥40 years; (B) change in glaucoma/OHT
prescriptions per 100 000 aged ≥40 years with income deprivation. Ninety-five per cent CIs of the regression lines are indicated
by broken lines. IMD, Index of Multiple Deprivation; OHT, ocular hypertension; PCT, primary care trust.
Heng JS, et al. BMJ Open 2016;6:e010429. doi:10.1136/bmjopen-2015-010429 9
Open Access
24. Prescribing - Health & Social Care Information Centre. Hscic.gov.uk.
2015. http://www.hscic.gov.uk/prescribing (accessed 1 July 2015).
25. McLennan D, Barnes H, Noble M, et al. The English indices of
deprivation 2010. London: Department for Communities and Local
Government. 2011. https://www.gov.uk/government/uploads/system/
uploads/attachment_data/file/6320/1870718.pdf (accessed 1 July
2015).
26. Edgar D, Romanay T, Lawrenson J, et al. Referral behaviour among
optometrists: Increase in the number of referrals from optometrists
following the publication of the April 2009 NICE guidelines for the
diagnosis and management of COAG and OHT in England and
Wales and its implications. Optom Pract 2010;11:33–8.
27. Fraser S, Bunce C, Wormald R, et al. Deprivation and
late presentation of glaucoma: case-control study. BMJ
2001;322:639–43.
28. Day F, Buchan JC, Cassells-Brown A, et al. A glaucoma equity
profile: correlating disease distribution with service provision and
uptake in a population in Northern England, UK. Eye (Lond)
2010;24:1478–85.
29. Ng WS, Agarwal PK, Sidiki S, et al. The effect of socio-economic
deprivation on severity of glaucoma at presentation. Br J Ophthalmol
2010;94:85–7.
30. Buys YM, Jin YP, Canadian Glaucoma Risk Factor Study Group.
Socioeconomic status as a risk factor for late presentation of
glaucoma in Canada. Can J Ophthalmol 2013;48:83–7.
31. Chung SD, Ho JD, Lin HC, et al. Incremental healthcare service
utilization for open-angle glaucoma: a population-based study.
J Glaucoma 2015;24:e116–20.
32. Rahman MQ, Beard SM, Discombe R, et al. Direct healthcare costs
of glaucoma treatment. Br J Ophthalmol 2013;97:720–4.
10 Heng JS, et al. BMJ Open 2016;6:e010429. doi:10.1136/bmjopen-2015-010429
Open Access
